Premium
Clinical Application and Pharmacodynamic Monitoring of Apixaban in a Patient with End‐Stage Renal Disease Requiring Chronic Hemodialysis
Author(s) -
Kufel Wesley D.,
Zayac Adam S.,
Lehmann David F.,
Miller Christopher D.
Publication year - 2016
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.1836
Subject(s) - apixaban , medicine , end stage renal disease , hemodialysis , warfarin , intensive care medicine , population , pharmacodynamics , dosing , rivaroxaban , surgery , atrial fibrillation , pharmacokinetics , environmental health
Despite prescribing guidance, limited data exist to describe the use of apixaban in patients with end‐stage renal disease ( ESRD ) requiring hemodialysis ( HD ). Current apixaban dosing recommendations for this patient population are based largely on a single‐dose pharmacokinetic study of eight patients. We describe the clinical application and pharmacodynamic monitoring of apixaban in a 62‐year‐old 156‐kg African‐American woman with nonvalvular atrial fibrillation and ESRD requiring hemodialysis who developed calciphylaxis while receiving warfarin therapy. Based on a multidisciplinary clinical judgment decision due to concern for drug accumulation after multiple doses in patients with ESRD receiving HD, she was anticoagulated with apixaban 2.5 mg twice/day, as opposed to 5 mg twice/day as recommended by the package insert. Antifactor Xa monitoring was used, and resultant peak and trough apixaban concentrations were above the upper limit of detection for our clinical laboratory (more than 2.00 IU /ml). On day 7 of her hospitalization, the patient developed gastrointestinal bleeding, and apixaban was discontinued; no further clinical signs of bleeding occurred during her subsequent hospitalization course. Use of the Naranjo Adverse Drug Reaction Probability Scale indicated a probable relationship (score of 6) between apixaban exposure and the manifestation of gastrointestinal bleeding. The patient ultimately died 44 days after the acute bleeding event; however, coagulation concerns were not implicated in the patient's death. To our knowledge, this is the first case report that describes apixaban use and associated antifactor Xa monitoring in a patient with ESRD receiving HD , and it provides concern for current apixaban dosing recommendations in this patient population. Further pharmacokinetic and clinical data are likely necessary to better characterize apixaban use in these patients to optimize safety and efficacy.